XOMA CORPORATION (FKA XOMA (US) LLC) for XOMA CORPORATION (FKA XOMA (US) LLC)
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 19, 2009 | $90,000 | Replaced |
| 3rd Quarter - Amendment | Oct 19, 2010 | $100,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
P.L. 111-5 American Recovery and Reinvestment Act 2009, issues pertaining to NIH funding opportunities.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BETH RADA | — |
| PATRICK JEROME SCANNON | — |
Defense DEF
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA) and overall medical countermeasure policy. Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Issues related to XOMAs anti-botulinum toxin program. Issues related to Pandemic Influenza National Strategy and Implementation Plan. H.R. 3293 LHHS Appropriations Act 2010, Public Health and Social Services Emergency Fund, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BETH RADA | — |
| PATRICK JEROME SCANNON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.